Acknowledgements
Cancer
CANCER
The authors thank study nurses, engineers and lab personnel in all hospitals, the patients who participated and their families for their valuable contribution to the trial. We thank the Norwegian Cancer Society and the South‐Eastern Norway Regional Health Authority for their funding and Roche for providing atezolizumab for this study. A graphical abstract image was created with 